We need your help to withdraw an unnecessary and potentially harmful co-sponsorship memo introduced by Representative Kathy Rapp. The co-sponsorship memo indicates that Representative

Rapp plans to introduce legislation to include the nalmefene product Zurnai to Act 135 specifically. Act 135 already includes nalmefene as a covered overdose reversal agent. The Act specifically encompasses “[N]aloxone hydrochloride or other similarly acting drugs approved by the United States Food and Drug Administration for the treatment of an opioid overdose.” Thus, nalmefene is already included and it is unnecessary to add this, or any, additional overdose reversal agents by brand name. Naming a particular brand of overdose reversal agent would give the misleading impression of endorsing that brand name agent.

Please take the time to send a (pre-filled) letter to Representative Rapp urging her to withdraw this unnecessary memo.